TL1A is encoded by TNFSF15 and is produced by endothelial cells. 5 Expression of TL1A can be induced in endothelial cells and chondrocytes under the influence of the inflammatory cytokines TNF and ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

TL1A, commonly called TNFSF15, belongs to the tumor necrosis factor family. TL1A is expressed in a variety of immune cells, including monocytes, macrophages, dendritic cells, T cells, and others.

Ulcerative colitis (UC) is a chronic disease that causes inflammation in the large intestine, affecting between 600,000 and ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

US-based biotechnology company Spyre Therapeutics has begun dosing healthy volunteers in Phase I studies of two investigational monoclonal antibodies. The drug candidates SPY002-091 and SPY002-072 ...

Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO. My name is Adam and I'll be your operator today. [Operator Instructions] I will now ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the ...

This increase was mainly due to an upfront payment of $500 million in connection with the collaboration on anti-TL1A asset, the sale of certain product rights, higher revenues from generic ...